Fusidic acid

Fusidic acid (Fusidate) a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid has no corticosteroid effects. Fusidic acid inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome. Fusidic acid holds promise for research in anticancer and anti-infective applications.^{[1][2][3][4][5]}. IC50 & Target:Bacterial^[1][2][3] In Vitro:Fusidic acid (100-200 μM, 72 h) primarily inhibits the proliferation of breast cancer (MCF-7, MDA-MB-231), thyroid cancer (8505C, TPC1), and cervical cancer (Caski, HeLa) cells through cell cycle arrest rather than apoptosis^[3].
Fusidic acid (0.01-100 × MIC, 24 h) exhibits stable intracellular antibacterial activity against methicillin-sensitive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in THP-1 cells, with potency comparable to Clindamycin (HY-B1455) and Linezolid (HY-10394). MIC at pH 7.4 was 0.25 mg/L, whereas MIC at pH 5.5 decreased to 0.01 mg/L^[4].
Fusidic acid (125 mg/L, 30 min) demonstrates enhanced antibacterial activity against methicillin-sensitive Staphylococcus aureus and significantly increased intracellular accumulation under acidic conditions (pH 5.5)^[4].
In Vivo:Fusidic acid (1 mg/mL, applied topically as a gel, 20 μL per mouse, once daily for 5 days) effectively reduced Candida albicans infection in the Cyclophosphamide (HY-17420)-induced immunosuppressed vaginal candidiasis mouse model and exhibited synergistic antifungal activity when combined with Fluconazole (HY-B0101)^[5].